A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Sinogliatin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hua Medicine
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint has not been met. (Change from baseline in HbA1c (For treatment dose 1; 75 mg QD (once a day))), according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Primary endpoint has been met. (Change from baseline in HbA1c (For treatment doses 2, 3 and 4)), according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top